BioSpace News Archive

All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”

At the end of 2016, there were an estimated 36.7 million people living with HIV across the globe. With a large and growing patient population, the market for HIV treatments is expected to grow to $22.5 billion by 2025.

United Therapeutics Corporation and SteadyMed Ltd. announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®.

The NGS field has been marked by a recent major trend, namely, the introduction of smaller, cheaper, and more user-friendly sequencers from most competitors, including Illumina, ThermoFisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies.

Prometic Life Sciences Inc. announced positive clinical data from its pivotal IVIG phase 3 clinical trial, meeting its clinical primary and secondary endpoints in adult patients suffering from primary immunodeficiencies (PID).

Eli Lilly and Company announced that Leena Gandhi, M.D., Ph.D., a prestigious thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology on June 25, 2018 to lead immuno-oncology medical development.

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA.

NovellusDx announced it has completed an equity financing of $6 million.

Compugen Ltd. announced that the Company will release its first quarter 2018 financial results on Wednesday, May 9, 2018.

InNEOvations™ at ENC 2018 Enable Deeper Insights into the Structure, Dynamics and Function of Structured, Unstructured and Membrane Proteins, and of Advanced Materials